70
Participants
Start Date
June 30, 2009
Primary Completion Date
May 31, 2010
Study Completion Date
July 31, 2010
ribavirin
200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
CTS-1027
5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
Placebo for ribavirin
Capsules identical to ribavirin in appearance containing inactive ingredients
Mount Sinai School of Medicine, New York
Washington Hospital Center, Washington D.C.
VCU-Medical College of Virginia, Richmond
University of NC at Chapel Hill, Chapel Hill
Duke University Health System, Durham
University of Florida, Gainsville
University of Alabama at Birmingham, Birmingham
Cleveland Clinic, Cleveland
Consultants of Clinical Research, Ohio GI and Liver Institute, Cincinnati
Henry Ford Medical Center-Columbus, Novi
MN Clinical Research Center, Plymouth
Mayo Clinic Rochester, Rochester
St. Louis University, St Louis
Tulane University Health Sciences Center, New Orleans
VA Medical Center, Houston, Houston
University of Colorado Health Science Center, Denver
Medical Associates Research Group, San Diego
Kaiser Permanante, San Diego
VA Medical Center, San Diego, San Diego
University of MA Mem Med Ctr, Worchester
Fundacion de Investigacion de Diego, Santurce
Lead Sponsor
Conatus Pharmaceuticals Inc.
INDUSTRY